Genomenon

Genomenon is a genomic intelligence company that transforms complex genetic data into actionable insights for patient diagnosis and precision medicine development. Serving both clinical diagnostics and precision therapeutics markets, Genomenon combines advanced AI technology with a team of scientific experts to unlock previously buried genomic data from clinical literature, organizing the world's genomic knowledge into powerful platforms that connect clinicians, researchers, and precision therapeutic developers with the most relevant evidence.

Genomenon's solutions are aligned with ACMG/AMP guidelines and address the growing challenge of navigating rapidly expanding genomic data, where finding clinically relevant insights remains difficult due to complexity and inconsistency across resources. The company supports rare disease diagnosis, cancer variant interpretation, and precision medicine programs from discovery through commercialization.

Software Platforms

• Mastermind Genomic Intelligence Platform: An AI-powered platform that analyzes and interprets vast genomic datasets, providing access to actionable insights from genomic literature on more than 27 million variants, as well as curated germline variant content to aid clinical decision-making.
• Cancer Knowledgebase (CKB): Genomenon's somatic knowledgebase used to interpret cancer variants, connecting them to relevant therapies and clinical trials for comprehensive and reliable genomic test interpretation.

Services

• Genomenon's expert team of genetic scientists provides tailored consulting services to support genomic projects across clinical diagnostics and precision therapeutics.
• Services include custom variant analysis, clinical trial support, and regulatory guidance, designed to address specific genomic challenges.
• Clinical Diagnostic Services are available to help laboratories and clinicians accelerate variant interpretation and increase diagnostic yield.

Data Solutions

• Genomenon offers access to an expansive, constantly updated database of curated genomic information, including gene-disease associations and variant data.
• Data is available in both indexed and curated forms, delivered via API or flat files for direct integration into tertiary analytic platforms.

Precision Therapeutics Offerings

• Real-World Evidence: Literature-driven real-world evidence solutions designed to accelerate drug development, expand disease insights, optimize clinical trials, and bring precision therapies to patients.
• Genetic Disease Sponsorship: A program enabling pharmaceutical and biotech companies to provide clinicians and researchers with open access to curated genetic evidence, reducing diagnostic barriers while advancing awareness, recognition, and scientific understanding of specific genetic diseases.

Clinical Diagnostics Capabilities

• Genomenon accelerates variant interpretation and increases diagnostic yield through rapid genomic literature search and comprehensive genomic insights.
• Platforms and services are designed to help clinicians never miss a diagnosis by surfacing the most relevant evidence at the gene and variant level.

Notable Customers and Partnerships

• Genomenon has partnered with Amicus Therapeutics to advance Fabry Disease awareness and diagnosis.
• Inozyme Pharma has leveraged Genomenon's literature-driven approach to enhance understanding of ENPP1 Deficiency through real-world evidence.
• UCB has partnered with Genomenon to close critical knowledge gaps, accelerate accurate diagnosis, and support global research for TK2 Deficiency (TK2d).
• Hartwig Medical Foundation uses CKB to enable comprehensive and reliable interpretation of genomic tests in a fully automated setting.

Trusted by industry leaders across clinical diagnostics and precision therapeutics, Genomenon continues to expand its impact by making genomic evidence more accessible, actionable, and aligned with the needs of clinicians, researchers, and drug developers working in rare disease and oncology.